SOURCE: AirWare Labs

AirWare Labs

January 27, 2014 08:10 ET

AIR ALLERGY™ by AirWare Labs Selected as a 2014 Visionary Award Finalist for the VISION® Consumer Products Conference

Patented Flu and Allergy-Blocking Nasal Filter Selected by INDA, the Association of the Nonwoven Fabrics Industry, to Present at VISION® in Dallas, January 27-30

SCOTTSDALE, AZ--(Marketwired - Jan 27, 2014) - AirWare Labs Corp. (OTCQB: AIRW) today announced that its AIR ALLERGY™ Advanced Nasal Filter has been selected as a 2014 Visionary Award Finalist for the VISION® Consumer Products Conference in Dallas, January 27-30, 2014.

Chosen by INDA, the Association of the Nonwoven Fabrics Industry, for its "demonstrated uniqueness, novelty and technical sophistication," the AIR ALLERGY™ patented nasal filter design effectively blocks airborne allergens like pollen, dust and pet dander, as well as bacteria and viruses that cause the flu by entering the body through the nasal passage.

"We are thrilled that AIR ALLERGY™ was selected by INDA as a Visionary Award finalist," said Jeffrey Rassás, President and CEO of AirWare Labs. "This prestigious nomination is a testimony of our commitment to using cutting-edge design in the development of easy to use products that enhance health, vitality -- and life overall -- by promoting optimal breathing." 

AirWare Labs Director of Marketing, Chase Herschman will give a presentation to VISION® attendees on the unique design and application of the AIR ALLERGY™ filter and its impact on the health and wellness industry, particularly as demand for products that defend against allergies and flu are at record levels.

In fact, market research firm Mintel recently reported that the cold, flu and allergy remedies market increased 22% from 2007-2012, with 7% of this growth happening between 2010 and 2012 -- due in large part to a severe 2012 allergy season. Mintel expects cold, flu and allergy sales to continue to climb as a result of the current cycle of milder temperatures and increased pollen counts.

In addition, Mintel notes an increasing demand for natural or alternative choices versus traditional medications for colds, flus and allergies. With its use of eucalyptus essential oil as a natural antibiotic defense against airborne allergens, viruses and bacteria, AIR ALLERGY™ is well positioned to capture a prominent place in this growing market, as reflected in its 2013 national rollout into 7,500 Walgreen's stores.

About AirWare Labs Corporation:

AirWare Labs Corp. [publicly traded as (OTCQB: AIRW)] provides patented and innovative technology solutions for consumer products that promote better health through breathing and enhanced wellbeing. AirWare Labs' products are marketed under the brand name of AIR®. AIR® products utilize an FDA approved medical grade silicone, molded as an intranasal Air Breathe dilator, to act as the delivery system. This AIR® microstructure enhances normal nasal airflow with every breath -- clinically proven to deliver up to 40% more oxygen. 

Some AIR® products are infused with essential oils with unique healing properties including antibacterial and therapeutic defense against airborne allergens, viruses and bacteria. AIR® Allergy and Travel products provide additional defense in the form of an integrated filter media from 3M to remove microscopic particles that carry viruses, allergens and bacteria. Other AIR® specialty products help provide and performance enhancements and relief from congestion, insomnia, headaches, nausea, and snoring. For more product information, please visit: or company information visit:

Forward-Looking Statement: The statements in this press release regarding any implied or perceived benefits from the release by AirWare Labs Corp. of its AIR ALLERGY™ product are forward-looking statements. Such statements involve risks and uncertainties, including, but not limited to, risks and effects of legal and administrative proceedings and governmental regulation, especially in a foreign country, future financial and operational results, competition, general economic conditions, and the ability to manage and continue growth.

Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual outcomes may vary materially from those indicated. Important factors that could cause actual results to differ materially from the forward-looking statements we make in this news release include the introduction of new technology, market conditions and those set forth in reports or documents we file from time to time with the SEC. We undertake no obligation to revise or update such statements to reflect current events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

Contact Information

  • Media Contact:
    Jennifer Breitegan

    Investor Relations:
    Jeffrey Rassas